M
Mabpharm Ltd
HKEX:2181
Mabpharm Ltd
HKEX:2181
Price:
0.44
HKD
1.15%
Market Closed
Market Cap:
HK$1.8B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
M
|
Mabpharm Ltd
HKEX:2181
|
CN |
Balance Sheet
Balance Sheet Decomposition
Mabpharm Ltd
Mabpharm Ltd
Balance Sheet Decomposition is not available for
Mabpharm Ltd
Mabpharm Ltd
Balance Sheet
Mabpharm Ltd
Mabpharm Ltd
Currency: CNY
| Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & Cash Equivalents |
76
|
198
|
589
|
485
|
82
|
34
|
173
|
89
|
109
|
|
| Cash |
76
|
198
|
589
|
485
|
82
|
34
|
173
|
89
|
109
|
|
| Short-Term Investments |
0
|
0
|
179
|
0
|
0
|
15
|
0
|
0
|
0
|
|
| Total Receivables |
13
|
2
|
7
|
16
|
52
|
41
|
44
|
104
|
155
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
1
|
10
|
19
|
95
|
155
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
51
|
31
|
24
|
9
|
0
|
|
| Inventory |
36
|
28
|
22
|
33
|
53
|
101
|
102
|
111
|
137
|
|
| Other Current Assets |
29
|
33
|
158
|
35
|
61
|
11
|
23
|
62
|
33
|
|
| Total Current Assets |
155
|
261
|
955
|
569
|
248
|
201
|
342
|
366
|
434
|
|
| PP&E Net |
113
|
123
|
332
|
513
|
561
|
704
|
687
|
614
|
569
|
|
| PP&E Gross |
113
|
123
|
332
|
513
|
561
|
704
|
687
|
614
|
0
|
|
| Accumulated Depreciation |
15
|
27
|
41
|
58
|
92
|
135
|
187
|
240
|
0
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
33
|
96
|
|
| Note Receivable |
16
|
20
|
28
|
34
|
9
|
2
|
2
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
5
|
70
|
81
|
47
|
82
|
10
|
4
|
3
|
54
|
|
| Total Assets |
289
N/A
|
473
+64%
|
1 396
+195%
|
1 163
-17%
|
900
-23%
|
918
+2%
|
1 035
+13%
|
1 016
-2%
|
1 153
+14%
|
|
| Liabilities | ||||||||||
| Accounts Payable |
1
|
12
|
4
|
4
|
13
|
17
|
161
|
181
|
244
|
|
| Accrued Liabilities |
5
|
21
|
57
|
48
|
69
|
67
|
59
|
48
|
0
|
|
| Short-Term Debt |
10
|
40
|
63
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
7
|
9
|
9
|
13
|
125
|
97
|
234
|
|
| Other Current Liabilities |
55
|
84
|
138
|
142
|
144
|
92
|
122
|
155
|
56
|
|
| Total Current Liabilities |
71
|
156
|
270
|
203
|
235
|
188
|
316
|
312
|
534
|
|
| Long-Term Debt |
65
|
65
|
35
|
32
|
36
|
113
|
135
|
196
|
93
|
|
| Minority Interest |
53
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
2
|
37
|
47
|
27
|
215
|
379
|
419
|
369
|
|
| Total Liabilities |
189
N/A
|
224
+18%
|
343
+53%
|
282
-18%
|
298
+6%
|
517
+73%
|
830
+61%
|
927
+12%
|
996
+7%
|
|
| Equity | ||||||||||
| Common Stock |
127
|
0
|
3
|
3
|
3
|
3
|
3
|
3
|
3
|
|
| Retained Earnings |
27
|
166
|
317
|
489
|
801
|
1 002
|
1 198
|
1 314
|
155
|
|
| Additional Paid In Capital |
0
|
410
|
1 401
|
1 401
|
1 401
|
1 401
|
1 401
|
1 401
|
0
|
|
| Other Equity |
0
|
5
|
33
|
33
|
33
|
33
|
0
|
0
|
0
|
|
| Total Equity |
100
N/A
|
250
+150%
|
1 054
+322%
|
881
-16%
|
602
-32%
|
401
-33%
|
205
-49%
|
89
-57%
|
157
+77%
|
|
| Total Liabilities & Equity |
289
N/A
|
473
+64%
|
1 396
+195%
|
1 163
-17%
|
900
-23%
|
918
+2%
|
1 035
+13%
|
1 016
-2%
|
1 153
+14%
|
|
| Shares Outstanding | ||||||||||
| Common Shares Outstanding |
3 416
|
3 416
|
4 124
|
4 124
|
4 124
|
4 124
|
4 124
|
4 124
|
4 124
|
|
Switch to:
Switch to:
See Also
Discover More
